<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">AJMB</journal-id><journal-title-group><journal-title>American Journal of Molecular Biology</journal-title></journal-title-group><issn pub-type="epub">2161-6620</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ajmb.2024.143009</article-id><article-id pub-id-type="publisher-id">AJMB-133124</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biomedical&amp;Life Sciences</subject></subj-group></article-categories><title-group><article-title>
 
 
  &lt;i&gt;In &lt;/i&gt;&lt;i&gt;Silico&lt;/i&gt; Screening of Potential Inhibitors against dPLA2 from Named Chinese Herbs for Identification of Compounds with Antivenom Effects Due to &lt;i&gt;Deinagkistrodon acutus &lt;/i&gt;Snake Bites
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xingyang</surname><given-names>Xiao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Mengyi</surname><given-names>Lai</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zechang</surname><given-names>Rao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jianzhong</surname><given-names>Huang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yiwei</surname><given-names>Xie</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Hongbin</surname><given-names>Zhang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Fuzhou Medical College of Nanchang University, Fuzhou, China</addr-line></aff><aff id="aff2"><addr-line>Medical College, Jinggangshan University, Ji&amp;amp;#8217;an, China</addr-line></aff><pub-date pub-type="epub"><day>15</day><month>05</month><year>2024</year></pub-date><volume>14</volume><issue>03</issue><fpage>107</fpage><lpage>125</lpage><history><date date-type="received"><day>12,</day>	<month>April</month>	<year>2024</year></date><date date-type="rev-recd"><day>12,</day>	<month>May</month>	<year>2024</year>	</date><date date-type="accepted"><day>15,</day>	<month>May</month>	<year>2024</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Phospholipase A2 (PLA2) is the key enzyme to the venom from &lt;i&gt;Deinagk&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;strodon acutus&lt;/i&gt; which is one of the highly venomous snakes in China. In addition to being a catalyst for the hydrolysis of phospholipases A2 from snake venom, it&amp;#8217;s well known that it possesses a broad spectrum of pharmacological activities, such as myotoxicity, neurotoxicity, cardiotoxicity, and hemolytic, anticoagulant and antiplatelet activities. However, snakebites are not efficiently treated by conventional serum therapy. Acute wounds can still cause poisoning and death. In order to find effective inhibitors of &lt;i&gt;Deinagkistrodon &lt;/i&gt;venom&lt;i&gt; &lt;/i&gt;acid phospholipase A2&lt;i&gt; &lt;/i&gt;(dPLA2), we obtained 385 compounds in 9 Chinese herbs from the TCMSP. These compounds were further performed to virtual screen using &lt;i&gt;in silico&lt;/i&gt; tools like ADMET analysis, molecular docking and molecular dynamics (MD) simulation. After Pharmacokinetics analysis, we found 7 candidate compounds. Besides, analysis of small molecule interactions with dPLA2 confirmed that the amino acid residues HIS47 and GLY29 are key targets. Because they bind not only to the natural substrate phosphatidylcholine and compounds known for having inhibitory functions, but also for combining with potential antidote molecules in Chinese herbal medicine. This study is the first to report experience with virtual screening for possible inhibitor of dPLA2, such as the interaction spatial structure, binding energy and binding interaction analysis, these experiences not only provide reference for further experimental research, but also have a guideline for the study of drug molecular mechanism of action.
 
</p></abstract><kwd-group><kwd>Chinese Herbal Medicine</kwd><kwd> Phospholipase A2 Inhibitor</kwd><kwd> Molecular Docking</kwd><kwd> Molecular Mechanism</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Venomous snakebite is a worldwide neglected public health emergency affecting predominantly poor residents in rural areas, especially in many tropical and subtropical countries [<xref ref-type="bibr" rid="scirp.133124-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref3">3</xref>] . According to estimation, between 1.2 million and 5.5 million snakebites happen annually all over the world. Moreover, approximately 400,000 victims have been left with permanent sequela, and 20,000 deaths occur each year [<xref ref-type="bibr" rid="scirp.133124-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref5">5</xref>] .</p><p>Deinagkistrodon acutus, also named as Agkistrodon acutus, is one of the hypertoxic snakes in China [<xref ref-type="bibr" rid="scirp.133124-ref6">6</xref>] . The venom of Deinagkistrodon acutus are heterogeneous mixtures of proteins or peptides that act on prey synergistically [<xref ref-type="bibr" rid="scirp.133124-ref7">7</xref>] . Jin H and coworkers found that the most abundant constituent of the Deinagkistrodon acutus venom was phospholipases A2 (30.0%), snaclec (21.0%), antithrombin (17.8%), thrombin (8.1%) and metalloproteinases (4.2%) [<xref ref-type="bibr" rid="scirp.133124-ref8">8</xref>] . Deinagkistrodon acutus phospholipases A2 (dPLA2) that calcium ion dependent plays an essential role in the pathological process on the patient [<xref ref-type="bibr" rid="scirp.133124-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref9">9</xref>] . Since this protease catalyzes the hydrolysis of the fatty acid ester at the sn-2 position of phospholipids releasing lysophospholipids and fatty acids [<xref ref-type="bibr" rid="scirp.133124-ref10">10</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref11">11</xref>] , and exerts a wide variety of relevant toxic actions such as myotoxic, neurotoxic, cardiotoxic, anticoagulant, cytotoxic, edematogenic, and proinflammatory effects [<xref ref-type="bibr" rid="scirp.133124-ref12">12</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref13">13</xref>] . Therefore, compounds capable of neutralizing dPLA2 may be effective in suppressing snake venom attacks.</p><p>Currently, the main treatment of snake envenomation is serum antivenom immunotherapy [<xref ref-type="bibr" rid="scirp.133124-ref14">14</xref>] . However, this approach experiences challenges with respect to poor antibody specificity, limited para-specificity, high incidence of adverse reactions, poor affordability and low availability to those who need them. Furthermore, it is difficult to neutralize the local tissue injury, since the rapid diffusion and reaction of the toxins present in Deinagkistrodon acutus venom reduce the antiserum efficiency [<xref ref-type="bibr" rid="scirp.133124-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref17">17</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref18">18</xref>] . Undoubtedly, research and development for simple and efficient antivenom to complement this therapy is a promising study field, and a combination of functional and structural assays will be used to test candidate ligands against dPLA2.</p><p>Compared with classical antivenom serum, medicinal plants used in folk medicine, are a potential source of antivenom natural bioactive inhibitory compounds [<xref ref-type="bibr" rid="scirp.133124-ref19">19</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref20">20</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref22">22</xref>] . Many studies indicate that some single-ingredient herbal medicines have potential therapeutic effects and value in the management of snakebites. Hedyotis diffusa Willd, Lobelia chinensis Lour, Houttuynia cordata Thunb, Sedum sarmentosum Bunge, Andrographis paniculata Nees, Pinellia ternata have demonstrated potential in the development of antivenom complementary therapies [<xref ref-type="bibr" rid="scirp.133124-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref25">25</xref>] . Pithayanukul et al. reported the ability of butanolic extracts from Eclipta prostata to neutralize the lethal effect, hemorrhagic effect and PLA2 activity of Calloselasma rhodostoma venom [<xref ref-type="bibr" rid="scirp.133124-ref26">26</xref>] . Phenolic compounds, isolated from the hexane extract of Curcuma longa roots, was shown to be a potent neutralizer of both the hemorrhagic effect induced by Bothrops jararaca and the lethal effect of Crotalus d. terrificus venoms [<xref ref-type="bibr" rid="scirp.133124-ref27">27</xref>] . Recently, the investigations of curative monomers in Chinese herbal medicines also made great progress [<xref ref-type="bibr" rid="scirp.133124-ref28">28</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref30">30</xref>] . Linsheng Zeng et al. screened 7 potential active ingredients from Cynanchum paniculatum against the venom of Bungarus multicinctus by Network Pharmacological method [<xref ref-type="bibr" rid="scirp.133124-ref31">31</xref>] . However, there are few reports about the treatment of Deinagkistrodon acutus venom by Chinese herbal monomer, dPLA2 have not been explored as a molecular target so far<sup> </sup> [<xref ref-type="bibr" rid="scirp.133124-ref32">32</xref>] .</p><p>Thus, in the present work, virtual screening, molecular docking, and molecular dynamics simulation were performed to test the potential inhibitors against dPLA2. Furthermore, we supplemented the molecular mechanism of interaction mode of complex, structural stability and flexibility, binding free energy et al.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. The Acquisition of Software and the Use of Databases</title><p>The software used in this study includes AutodockTools-4.2.6, Autodock vina-1.1.2, Pymol-2.4.0 and GROMACS-2020.6, OpenBabel-3.1.1, Discovery studios Visualization-19.1.0 (DS), APBS-3.0.0 (Adaptive poisson-Boltzmann Solver) and gmx_mmpbsa.bsh; The database used in this study includes TCMSP-Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (tcmsp-e.com), Protein Data Bank(RCSB PDB: Homepage).</p><p>Among them, Autodock vina, used for molecular docking, is downloaded from AutoDock (scripps.edu); Pymol, which is installed using the whole file provided by UC Irvine Laboratory, was employed to process molecular docking image; Discovery Studio was applied for protein and small molecule preparation, virtual screening (ADMET), batch molecular docking and protein ligand complex interaction display and 2D mapping; TCMSP database was used to obtain small molecules of target Chinese herbal medicine and preliminary screening; OpenBabel is able to convert files, it is downloaded from https://openbabel.org/; GROMACS is available in Molecular Dynamics module (https://www.gromacs.org/); APBS and gmx_mmpbsa.bsh are used for calculating the binding free energy, they were downloaded from https://github.com/Electrostatics/apbs/releases and https://github.com/Jerkwin/gmxtool respectively.</p></sec><sec id="s2_2"><title>2.2. Ligand and Receptor Preparation</title><sec id="s2_2_1"><title>2.2.1. Ligand Preparation</title><p>Based on TCMSP, 9 Chinese herbal medicines (Eclipta prostrata L, Hedyotis diffusa Willd, Lobelia chinensis Lour, Houttuynia cordata Thunb, Sedum sarmentosum Bunge, Andrographis paniculata Nees, Cynanchum paniculatum, Curcuma longa L, Pinellia ternata), which have been claimed to have a therapeutic effect on snakebite, were selected for this study. They were retrieved in TCMSP and then screened according to the criterion of drug-like properties (DL) ≥ 0.18 and oral bioavailability (OB) ≥ 30% [<xref ref-type="bibr" rid="scirp.133124-ref33">33</xref>] . Then those compounds which satisfied the standard, were downloaded as ligands and imported into OpenBabel for building files as “sd” or “sdf” format. Subsequently, these files were inputted into DS Minimize Ligands module for hydrogenation, adding charge and structural optimization under CHARMm force field.</p></sec><sec id="s2_2_2"><title>2.2.2. Receptor Preparation</title><p>The important clinical manifestations of patients who were bitten by Deinagkistrodon acutus are tissue edema and bleeding, which are closely associated with acidic PLA2 in snake venom. So the inhibition of acidic PLA2, has important significance for relieving tissue edema and bleeding. Based on it search for the acidic PLA2 in the PDB database as a receptor for molecular docking, the results showed that there is only one acidic PLA2 of known structure (PDB ID: 1IJL).The crystal structure of dPLA2 (PDB ID: 1ijl) was accessed from Protein Data Bank (PDB) of RCSB (http://www.rcsb.org/) as receptor. Subsequently, the protein was modified using DS, including removal of water, adding hydrogen, and replenishing of lost residues. By means of CHARMm force field (OPLS3e), the protein structure was optimized to assure the structural accuracy of final receptor [<xref ref-type="bibr" rid="scirp.133124-ref10">10</xref>] .<sup> </sup></p></sec></sec><sec id="s2_3"><title>2.3. Pharmacokinetics Analysis</title><p>ADME screening and toxicological prediction were used for virtual screening of the identified small molecules. The absorption, distribution, metabolism, excretion and toxicity (ADMET) properties were analyzed and assessed using DS Small Molecules-ADMET online server [<xref ref-type="bibr" rid="scirp.133124-ref34">34</xref>] . The evaluation criterion of ADMET was that Absorption_level ≤ 1, 2 ≤ Solubility_level ≤ 4, BBB_level ≤ 3. The prediction model we use was Developmental Toxicity Potential DTP, Rat Oral LD50 and Ames Mutagenicity. Finally the toxicity prediction results were derived.</p></sec><sec id="s2_4"><title>2.4. Molecular Docking</title><sec id="s2_4_1"><title>2.4.1. Batch Molecular Docking</title><p>The compounds through pharmacokinetics screened was performed to batch molecular docking by the Dock Ligand modules. The binding sites were Y27, G29, G31, H47, D48, Y51, and D98, so the active center was X = 6.826, Y = 12.735, Z = 50.709, the grid was set as 15 &#215; 15 &#215; 15. Docking type was set as Libdock. Moreover, the docking score prediction of the molecules was performed, each molecule retained the highest score and arranged these scores in descending order.</p></sec><sec id="s2_4_2"><title>2.4.2. Precision Molecular Docking</title><p>The molecules with the top score conformations were further redocked using Autodock vina with the same parameters as batch molecular docking to generate binding energy, hydrogen bonding and hydrophobic interaction results. The docking results were saved in pdb format respectively. Then we imported the results into PYMOL in pdbqt format for visualization processing and into DS in pdb format to obtain 2D structure diagram.</p></sec></sec><sec id="s2_5"><title>2.5. Molecular Dynamics (MD) Simulations</title><p>Molecular dynamics simulation (at 100 ns) was employed to explore the stability of ligand-protein combinations and analyze the molecular mechanisms of protein-target interactions. The top docking score of compound conformations from the molecular docking process were subjected to the GROMACS 2020 (Groningen Machine for Chemical Simulations Calculations) [<xref ref-type="bibr" rid="scirp.133124-ref35">35</xref>] and Amber99sb-ildn force field for Molecular dynamics simulation.</p><sec id="s2_5_1"><title>2.5.1. Preparation Topology</title><p>Initial configurations of ligands were produced with ACPYPE (http://bio2byte.be/acpype/) Server to prepare the topology structures, simultaneously, the Pdb2gmx was applied to generate the protein topology and structure files.</p></sec><sec id="s2_5_2"><title>2.5.2. Preparation Reaction System</title><p>Firstly, the protein was centered on the cube box. Then the simple point charge (SPC) water model was solved. For the purpose of energy minimization of the system, we eliminated collisions at atomic positions through implement the fastest descent method. Due to the exposed residual charge of the protein given the system -12 net charge, so 12 Na<sup>+</sup> counter ions were added to conform electroneutrality ahead of the actual simulation. Next, the band constraint of LINCS algorithm was applied to the system, the long range electrostatic interaction was calculated by particle grid Ewald (PME) algorithm. Afterwards, the NVT and NPT ensembles (constant number of atoms, volume, pressure, and temperature) were performed to the system for the MD simulation studies. In addition, at 1.4 nm, the cutoff values of Van der Waals interaction and short range Coulomb were set respectively in the system, periodic boundary conditions were applied to the whole three-dimensional spaces. Finally, 100 ns intervals of MD simulations were carried out for all the complexes with the time step 2fs, as well as the following data were investigated, including RMSD, RMSF and potential energy of protein-ligand complexes, radial distribution of ligand, complexes free energy profile and hydrogen bonds.</p></sec></sec><sec id="s2_6"><title>2.6. MD Data Processing</title><p>It was discovered that the protein or the ligand-protein Root Mean Square Deviation (RMSD) and Root Mean Square Fluctuation (RMSF) plots, as well as patterns of protein-ligand interaction, are markers of ligand stability.</p><sec id="s2_6_1"><title>2.6.1. RMSD (Root Mean Square Deviation)</title><p>The root mean square deviation reflects the degree of data deviation from the mean value. In the dynamic simulation of protein-ligand complexes, it represents the degree of fit or deviation between the conformation after simulated “nt” time and the initial conformation. The greater the RMSD value, the greater the difference between the conformation after “nt” time simulation and the original conformation, that is, the worse the conformation stability. On the contrary, the more stable it is. The calculation formula is below:</p><p>RMSD = 1 N ∑ i = 1 N ( δ i − δ 0 ) 2</p><p>δ i represents the position of the conformation of the I-th frame, and δ 0 represents the position of the initial conformation.</p></sec><sec id="s2_6_2"><title>2.6.2. RMSF (Root Mean Square Fluctuation)</title><p>The root-mean-square fluctuation indicates the position change of an atom over a period of time. It also reflects the degree of flexibility of the atom. The calculation was derived as follows:</p><p>RMSF = 1 T ∑ t j = 1 T ( x i ( t j ) − x 0 ) 2</p><p>x i ( t j ) − x 0 represents the position of an atom at “t” time subtraction the position at the initial time.</p></sec></sec><sec id="s2_7"><title>2.7. MM-PBSA Calculation (Molecular Mechanics-Poisson-Boltzmann Superficial Area)</title><p>The expected binding energy and the standard deviation were calculated for the complete 100 ns time interval using gmx_mmpbsa.bsh. The working principle is to count the difference between the binding free energy of two solvated molecules in bound and unbound states, or to compare the free energy of the same molecule in different solvated conformations. That is, decomposing the binding free energy into molecular mechanical terms and solvation energy, they were computed separately. The binding free energy was calculated using the following formula:</p><p>Δ G bind ， solv 0 = Δ G bind , vacuum 0 + Δ G solv ， complex 0 − ( Δ G solv ， ligand 0 + Δ G solv ， receptor 0 )</p><p>Δ G bind ， solv 0 denotes the binding free energy under solvent; Δ G bind , vacuum 0 expresses the binding energy of the interaction between molecules and proteins with the addition of solvent; Δ G solv ， complex 0 represents the energy of the complexes in the solvent; Δ G solv ， complex 0 represents the energy of the receptor in the solvent.</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><sec id="s3_1"><title>3.1. Screening Preliminary</title><sec id="s3_1_1"><title>3.1.1. TCMSP Analysis</title><p>Approximately, 385 chemical components from 9 kinds of herbs (Eclipta prostrata L, Hedyotis diffusa Willd, Lobelia chinensis Lour, Houttuynia cordata Thunb, Sedum sarmentosum Bunge, Andrographis paniculata Nees, Cynanchum paniculatum, Curcuma longa L, Pinellia ternata), with potential antivenomous activity,were carried out to virtual screening by TCMSP. Under the above conditions, 89 compounds were selected for further assessment.</p></sec><sec id="s3_1_2"><title>3.1.2. Pharmacokinetics Analysis</title><p>To exclude these molecules that may be harmful to human body, it is critical to screen the candidates to fit for drug-like properties. After ADME analysis,the distribution of 89 molecules are as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>(a). After ADME screening, 7 molecules were identified with a greater potential as the inhibitors against dPLA2 as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>(b). They are presented in <xref ref-type="table" rid="table1">Table 1</xref> as, 3-[(2S,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-(hydroxymethyl)-7-methoxy-2, 3-dihydrobenzofuran-5-yl] propyl acetate; Ruvoside-qt; 14-deoxy-12-methoxyandrographolide; 14-deoxy-11-oxo-andrographolide; (3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl) piperazine-2,5-quinone (MOL006957); tomentogenin (MOL005622) and Isoramanone. Their chemical structures are shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>(c).</p><p>The toxicity of seven molecules was predicted using three models of DS: Mutagenicity, Developmental_Toxicity_Potential and Rat_Oral_LD50. A prediction score less than 0 indicates relative nontoxicity, a score greater than 0 indicates toxicity, and a larger value indicates greater toxicity. Toxicity prediction revealed that of the seven compounds, only 14-deoxy-11-oxo-andrographolide had no potential developmental toxicity. From the perspective of oral half-lethal dose in rats, the highest value was found on tomentogenin (8.12 g/kg), with the potential developmental toxicity of 0.47699, indicating that it was less toxic. From the perspective of mutagenicity, none of the 7 molecules were teratogenic, and the lowest teratogenic was Ruvoside-qt (−37.5246). Moreover the oral lethal dose of Ruvoside-qt was 6.38, which was relatively large, suggesting that it was less toxic.</p></sec></sec><sec id="s3_2"><title>3.2. Molecular Docking</title><p>We learned from the PDB database that the amino acid residues (Y27, G29, G31 and D48) of the calcium ion binding ring are the active sites of dPLA2. It indicated that dPLA2 is a calcium-dependent protease. However, the enzyme activity of dPLA2 is determined by three main factors, including integrity of the active site (His48, Asp49, Tyr52, Asp99), coordination of Ca<sup>2+</sup> cofactors (Tyr28, Gly30, Gly32 and Asp49), and Enzyme adsorption on outer surface of membrane lipid [<xref ref-type="bibr" rid="scirp.133124-ref36">36</xref>] . As a result, the regions composed of Y27, G29, G31, H47, D48, and D89 were set as binding sites. The center was X = 6.826, Y = 12.735, Z = 50.709, and the grid was 15 &#215; 15 &#215; 15. The above parameters were used for the following docking experiments.</p><sec id="s3_2_1"><title>3.2.1. Batch Molecular Docking Results</title><p>Libdock batch molecular docking was performed to predict the binding possibility of the seven ligands to the active site of dPLA2. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the top docking score is Ruvoside-qt with 140.465, which indicated that Ruvoside-qt was the most likely to combine and function with dPLA2. The other compounds were sorted by score for 3-[(2S,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-(hydroxylmethyl)-7-methoxy-2,3-dihydrobenzofuran-5-yl] propyl acetate; tomentogenin; 14-deoxy-11-oxo-andrographolide; 14-deoxy-12-methoxyandrographolide et al.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> The virtual screening results</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >number</th><th align="center" valign="middle" >chemical name</th><th align="center" valign="middle" >source</th><th align="center" valign="middle" >DTP score</th><th align="center" valign="middle" >Rat oral LD50</th><th align="center" valign="middle" >Ames score</th><th align="center" valign="middle" >Libscord</th></tr></thead><tr><td align="center" valign="middle" >MOL004350</td><td align="center" valign="middle" >Ruvoside-qt</td><td align="center" valign="middle" >Houttuynia cordata</td><td align="center" valign="middle" >5.06455</td><td align="center" valign="middle" >6.38</td><td align="center" valign="middle" >−37.5247</td><td align="center" valign="middle" >140.465</td></tr><tr><td align="center" valign="middle" >MOL012225</td><td align="center" valign="middle" >3-[(2S,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-(hydroxymethyl)-7-methoxy-2,3-dihydrobenzofuran-5-yl]propyl acetate</td><td align="center" valign="middle" >Lobelia chinensis Lour</td><td align="center" valign="middle" >3.27856</td><td align="center" valign="middle" >4.15</td><td align="center" valign="middle" >−30.4556</td><td align="center" valign="middle" >137.676</td></tr><tr><td align="center" valign="middle" >MOL005622</td><td align="center" valign="middle" >tomentogenin</td><td align="center" valign="middle" >Cynanchum paniculatum (Bunge) Kitag</td><td align="center" valign="middle" >0.47699</td><td align="center" valign="middle" >8.12</td><td align="center" valign="middle" >−17.0531</td><td align="center" valign="middle" >130.195</td></tr><tr><td align="center" valign="middle" >MOL008203</td><td align="center" valign="middle" >14-deoxy-11-oxo-andrographolide</td><td align="center" valign="middle" >Andrographis paniculata (Burm. f.) Nees</td><td align="center" valign="middle" >−0.713909</td><td align="center" valign="middle" >2.84</td><td align="center" valign="middle" >−21.9184</td><td align="center" valign="middle" >128.67</td></tr><tr><td align="center" valign="middle" >MOL008213</td><td align="center" valign="middle" >14-deoxy-12-methoxyandrographolide</td><td align="center" valign="middle" >Andrographis paniculata (Burm. f.) Nees</td><td align="center" valign="middle" >0.689345</td><td align="center" valign="middle" >2.80</td><td align="center" valign="middle" >−29.2365</td><td align="center" valign="middle" >124.441</td></tr><tr><td align="center" valign="middle" >MOL006957</td><td align="center" valign="middle" >(3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl)piperazine-2,5-quinone</td><td align="center" valign="middle" >Pinellia ternata</td><td align="center" valign="middle" >3.64066</td><td align="center" valign="middle" >0.84</td><td align="center" valign="middle" >−15.1692</td><td align="center" valign="middle" >120.725</td></tr><tr><td align="center" valign="middle" >MOL003851</td><td align="center" valign="middle" >Isoramanone</td><td align="center" valign="middle" >Houttuynia cordata</td><td align="center" valign="middle" >3.75027</td><td align="center" valign="middle" >1.81</td><td align="center" valign="middle" >−28.9906</td><td align="center" valign="middle" >117.005</td></tr></tbody></table></table-wrap><p>Note: DTP is the potential for developing toxicity, the smaller the value indicates the smaller the potential for developing toxicity, positive value has the potential for developing toxicity (Toxic), negative value indicates no potential for developing toxicity (non-Toxic); Ames score is mutagenicity, the smaller the value indicates the lower mutagenicity, positive value indicates mutation (Mutagenicity), and negative value indicates no mutation (non-Mutagenicity).</p></sec><sec id="s3_2_2"><title>3.2.2. Positive Control-Phosphatidylcholine</title><p>Phosphatidylcholine (1,2-Diacyl-SN-glycero-3-phosphocholine), the natural substrate of dPLA2, is the most abundant phosphatidylcholine component in cell membranes. The hydrolase dPLA2 breakdowns membrane phospholipids, which generates inflammatory mediators, such as arachidonic acid, prostaglandin and platelet activating factor, causing inflammation in humans. Our use of phosphatidylcholine-dPLA2 complex as a positive control to screen for competitive inhibitors is highly convincing. It can also verify the accuracy of the active site.</p><p>The experiments in vitro incubation found that Gallic acid and pyrogallol shown obvious inhibitory effects on dPLA2 in a concentration-dependent manner [<xref ref-type="bibr" rid="scirp.133124-ref37">37</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref38">38</xref>] . For this reason, we employed Gallic acid and pyrogallol to interact with dPLA2 respectively, to verify the feasibility of the active site, laying a foundation for the accuracy of molecular docking and the feasibility of screening.</p></sec><sec id="s3_2_3"><title>3.2.3. Precision Molecular Docking Results</title><p>Autodock vina was considered as an important computational tool in search of the interaction mode of the complex. It can more precisely predict the binding interactions between the compounds and the active site of the target protein. In this way, AutoDock Vina generated a docked complex for each ligand with various conformation and affinity scores. The best protein-ligand complex docked pose were analyzed and graphically visualized by DS.</p><p>As shown in <xref ref-type="table" rid="table2">Table 2</xref>, molecular docking revealed that phosphatidylcholine</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the molecular docking interactions</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >number</th><th align="center" valign="middle" >chemical name</th><th align="center" valign="middle" >binding energy</th><th align="center" valign="middle" >hydrogen bond</th><th align="center" valign="middle" >hydrophobic</th><th align="center" valign="middle" >Action with Ca</th><th align="center" valign="middle" >Other functions</th></tr></thead><tr><td align="center" valign="middle" >MOL006957</td><td align="center" valign="middle" >(3S,6S)-3-(benzyl)-6-(4-hydroxybenzyl)piperazine-2,5-quinone</td><td align="center" valign="middle" >−9.0</td><td align="center" valign="middle" >GLY29 GLY31</td><td align="center" valign="middle" >TRP30</td><td align="center" valign="middle" >Metal-Acceptor</td><td align="center" valign="middle" >Pi-Cation: LYS60 Pi-sulfer: CYS44 C-H: HIS47</td></tr><tr><td align="center" valign="middle" >MOL003851</td><td align="center" valign="middle" >Isoramanone</td><td align="center" valign="middle" >−8.1</td><td align="center" valign="middle" >HIS47 ASP48</td><td align="center" valign="middle" >LEU2 TRP30 TYR51</td><td align="center" valign="middle" >Metal-Acceptor</td><td align="center" valign="middle" >/</td></tr><tr><td align="center" valign="middle" >MOL012225</td><td align="center" valign="middle" >3-[(2S,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-(hydroxymethyl)-7-methoxy-2,3-dihydrobenzofuran-5-yl]propyl acetate</td><td align="center" valign="middle" >−7.7</td><td align="center" valign="middle" >HIS47</td><td align="center" valign="middle" >PHE5 GLY29</td><td align="center" valign="middle" >Pi-Anion</td><td align="center" valign="middle" >VDW: TRP30 Pi-Cation: ASP48</td></tr><tr><td align="center" valign="middle" >MOL004350</td><td align="center" valign="middle" >Ruvoside-qt</td><td align="center" valign="middle" >−6.9</td><td align="center" valign="middle" >ASP48</td><td align="center" valign="middle" >TRP30 HIS47 TYR51 LYS60</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >/</td></tr><tr><td align="center" valign="middle" >MOL008203</td><td align="center" valign="middle" >14-deoxy-11-oxo-andrographolide</td><td align="center" valign="middle" >−6.8</td><td align="center" valign="middle" >GLY29 ASP48 LYS60</td><td align="center" valign="middle" >LEU2 TRP30 TYR51 LYS60</td><td align="center" valign="middle" >Unfavorable Bump</td><td align="center" valign="middle" >/</td></tr><tr><td align="center" valign="middle" >MOL005622</td><td align="center" valign="middle" >tomentogenin</td><td align="center" valign="middle" >−6.7</td><td align="center" valign="middle" >ASP48</td><td align="center" valign="middle" >LEU2 TRP30 TYR51 LYS60</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >/</td></tr><tr><td align="center" valign="middle" >MOL008213</td><td align="center" valign="middle" >14-deoxy-12-methoxyandrographolide</td><td align="center" valign="middle" >−5.8</td><td align="center" valign="middle" >GLY31 ASP48</td><td align="center" valign="middle" >TRP30 TYR51</td><td align="center" valign="middle" >Metal-Acceptor</td><td align="center" valign="middle" >/</td></tr><tr><td align="center" valign="middle" >MOL008290</td><td align="center" valign="middle" >1,2-diacyl-sn-glycero-3-phosphocholine</td><td align="center" valign="middle" >−5.7</td><td align="center" valign="middle" >TRP30 GLY31 HIS47 LYS60</td><td align="center" valign="middle" >CYS44 HIS47 PRO120</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >Pi-Anion: TRP30 Attractive charge: LYS60 C-H: GLY32</td></tr><tr><td align="center" valign="middle" >MOL000513</td><td align="center" valign="middle" >Gallic acid</td><td align="center" valign="middle" >−6.3</td><td align="center" valign="middle" >TYR21 GLY29 HIS47</td><td align="center" valign="middle" >PHE5 HIS47</td><td align="center" valign="middle" >Metal-Acceptor</td><td align="center" valign="middle" >/</td></tr><tr><td align="center" valign="middle" >MOL000106</td><td align="center" valign="middle" >pyrogallol</td><td align="center" valign="middle" >−5.7</td><td align="center" valign="middle" >TYR27 GLY29 HIS47</td><td align="center" valign="middle" >PHE5 TRP20</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >/</td></tr></tbody></table></table-wrap><p>Note: <xref ref-type="table" rid="table2">Table 2</xref> shows the docking results of the seven small molecules with dPLA 2 molecules (top 7), and the docking results of dPLA 2 with phosphatidylcholine, gallic acid and catechol (last 3). In Table, MOL006957 to MOL008213 are the potential active components obtained in virtual screening according to the size of docking binding energy; MOL008290 to MOL000106 are the small molecules that inhibit PLA2 and used as a positive control. The abbreviated VDW applied in the table represents the van der Waals.</p><p>combine well with the protein in the position of TRP30, GLY31, HIS47 and LYS60 through hydrogen bonds as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>(b), hydrophobic interactions with CYS44, HIS47 and PRO120, anion interactions with TRP30, charge attraction interactions with LYS60, and C-H bonds with GLY32. These binding</p><p>sites are similar to the dPLA2 active site. Meanwhile comparing with phosphatidylcholine, gallic acid and pyrogallol have similar dPLA2 binding sites, both gallic acid and pyrogallol form hydrogen bonds with GLY29 and HIS47 as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>(a). Besides, all three form hydrogen bonds and hydrophobic interactions with HIS47. It then suggested that HIS47 may perform an important part in the catalytic activity of dPLA2.</p><p>In terms of binding energy, pyrogallol and phosphatidylcholine have the same binding energy of −5.7 kJ/mol, gallic acid −6.3 kJ/mol and combine with Ca<sup>2+</sup> by metallic bond. Thus, according to the interaction of three controls with dPLA2, the catalytic active center of the receptor is a calcium-ion binding ring composed of TYR27, GLY29, GLY31, HIS47 and ASP48. Moreover HIS47 and GLY29 may be key targets in the catalytic activity.</p><p>After docking, 7 molecules are able to combine with the target protein of dPLA2. The binding energies are all less than −5.7 kJ/mol. The lowest binding energy is MOL006957 (−9.0 kJ/mol). The second least binding energy for Isoramanone being −8.1 kJ/mol. As it is known that the lower the energy, the stronger the bond, they were the ligands with the most binding affinity to the receptor. In terms of interaction, MOL006957 forms hydrogen bonds with GLY29 and GLY31 as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>(d), hydrophobic bonds with TRP30, metallic bonds with Ca<sup>2+</sup>, cations interaction with LYS60, and CYS 44 forms the Pi-sulfur bond and the C-H bond with HIS47, which is most similar to phosphatidylcholine in general. Isoramanone forms hydrogen bond interaction with HIS47 and ASP48 as shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>(c), hydrophobic interaction with LEU2, TRP30 and TYR51, and metallic bond with Ca<sup>2+</sup>. Consequently, MOL006957 is most likely to be the ligand of dPLA2, which was further verified by molecular dynamics simulations.</p></sec></sec><sec id="s3_3"><title>3.3. Molecular Dynamics (MD) Simulations</title><sec id="s3_3_1"><title>3.3.1. RMSD and RMSF Analysis</title><p><xref ref-type="fig" rid="fig3">Figure 3</xref>(a) shows RMSD of the backbone of the seven protein-ligand complexes which changed with the time over 100 ns. A conclusion can be drawn from the picture that after simulation, the conformations of these seven complexes tended to converge. Comparing with the initial conformation, the deviation of all the complexes were less than 0.4 nm. In particular, the RMSD of MOL005622-dPLA2 and MOL006957-dPLA2 complexes were lower than other compounds. The result indicated that the two compounds were relatively stable over 100 ns. Then, in comparison to dPLA2, RMSD of MOL005622-dPLA2 and MOL006957-dPLA2 complexes was lower overall and it suggested that the structural flexibility of dPLA2 were reduced after binding ligands, as shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>(b).</p><p>RMSF reflected the vibration of each complex compared with the initial conformation, as shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>(c). In comparison to other compounds, there was the smallest molecular vibration in MOL006957-dPLA2 complex, which reflects that it is more stable than other compounds at the molecular level. Simultaneously comparing with dPLA2, MOL006957-dPLA2 molecular vibration was</p><p>significantly weakened, as shown in <xref ref-type="fig" rid="fig3">Figure 3</xref>(d).</p></sec><sec id="s3_3_2"><title>3.3.2. Free Energy Topography (FEL) Analysis and Hydrogen Bond Analysis</title><p>FEL is able to evaluate comprehensively the free energy of different conformations in simulation process through the following two parameters: root mean square error (RMSD) and gyrate. As shown in <xref ref-type="fig" rid="fig4">Figure 4</xref>(a), the lower the energy (the darker the blue), the more stable the conformation. Through the parameter files, it was found that the lowest energy conformation was frame 3670 and frame 3680, and compared the lowest energy conformation with the initial conformation, as shown in the <xref ref-type="fig" rid="fig4">Figure 4</xref>(b). Furthermore, hydrogen bonds play an important role in ligand-receptor interactions, and the number of hydrogen bonds is also an important index to judge the binding stability of protein-ligand complexes. As shown in the <xref ref-type="fig" rid="fig4">Figure 4</xref>(c), the overall number of hydrogen bonds increased with the extension of simulation time, and finally remained at 3 to 4.</p></sec></sec><sec id="s3_4"><title>3.4. Binding Free Energy Calculation</title><p>The Poisson-Boltzmann superficial area approach from molecular mechanics (MM/PBSA) was used to determine the binding free energy of protein-ligand complexes. In actual fact, the amount of spuriously positive outcomes in molecular docking study is decreased owing to this accurate quantum mechanical computation.</p><p>The binding free energy reflects the stability of the ligand-protein complexes in the solvent, and the influence of the solvent on the process of ligand combining with protein. The trajectory of two complexes (MOL006957-dPLA2 and MOL005622-dPLA2) with the best molecular dynamics simulation results, were performed to compute the binding free energy. Then the stability of the complexes in the solvent was checked. The results are shown in <xref ref-type="table" rid="table3">Table 3</xref>. The average binding energy of MOL006957-dPLA2 and MOL005622-dPLA2 in solvent respectively are −99.334 kJ/mol and −73.242 kJ/mol, which expresses that the solvent has little effect on the stability of the complex, and the ligand binding is quite stable. However, the average binding energy of others are relatively low, revealed that the solvent has a great influence on the stability of the complex, and the ligand binding is unstable. Thus, we provide stronger evidence for the potential inhibitory effect of MOL006957 on the dPLA2 venom of Agkistrodon acutus.</p></sec></sec><sec id="s4"><title>4. Conclusions</title><p>Pinellia ternata is one of the most commonly used traditional Chinese medicinal plants. It has been demonstrated to be highly effective for treating cough, vomiting, infection, and inflammatory diseases. Modern pharmacological investigations have demonstrated its multiple activities, such as antitussive, expectorant, antiemetic, antitumor, antibacterial, and sedative-hypnotic activities [<xref ref-type="bibr" rid="scirp.133124-ref39">39</xref>] [<xref ref-type="bibr" rid="scirp.133124-ref40">40</xref>] .</p><p>The compound MOL006957 screened in this study is one of the active potential drug like molecule of Pinellia [<xref ref-type="bibr" rid="scirp.133124-ref41">41</xref>] . It has been reported that the active</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Comparison of the binding free-energy results of compounds</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >compound</th><th align="center" valign="middle" >dH</th><th align="center" valign="middle" >MM</th><th align="center" valign="middle" >PB</th><th align="center" valign="middle" >SA</th><th align="center" valign="middle" >COU</th><th align="center" valign="middle" >VDW</th><th align="center" valign="middle" >dG</th><th align="center" valign="middle" >Affinity</th></tr></thead><tr><td align="center" valign="middle" >Mol003851-dPLA2</td><td align="center" valign="middle" >−98.005</td><td align="center" valign="middle" >−98.005</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−18.345</td><td align="center" valign="middle" >−79.660</td><td align="center" valign="middle" >−53.978</td><td align="center" valign="middle" >Strong</td></tr><tr><td align="center" valign="middle" >NOL004350-dPLA2</td><td align="center" valign="middle" >−40.840</td><td align="center" valign="middle" >−40.840</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >6.501</td><td align="center" valign="middle" >−47.342</td><td align="center" valign="middle" >−4.305</td><td align="center" valign="middle" >Weak</td></tr><tr><td align="center" valign="middle" >MOL005622-dPLA2</td><td align="center" valign="middle" >−103.381</td><td align="center" valign="middle" >−103.381</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−17.283</td><td align="center" valign="middle" >−86.098</td><td align="center" valign="middle" >−73.242</td><td align="center" valign="middle" >Very strong</td></tr><tr><td align="center" valign="middle" >MOL006957-dPLA2</td><td align="center" valign="middle" >−113.726</td><td align="center" valign="middle" >−113.726</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >21.997</td><td align="center" valign="middle" >−135.724</td><td align="center" valign="middle" >−99.334</td><td align="center" valign="middle" >Very strong</td></tr><tr><td align="center" valign="middle" >MOL008203-dPLA2</td><td align="center" valign="middle" >−127.503</td><td align="center" valign="middle" >−127.503</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−31.177</td><td align="center" valign="middle" >−96.325</td><td align="center" valign="middle" >−2.960</td><td align="center" valign="middle" >Weak</td></tr><tr><td align="center" valign="middle" >MOL008213-dPLA2</td><td align="center" valign="middle" >−122.776</td><td align="center" valign="middle" >−122.776</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >13.856</td><td align="center" valign="middle" >−136.632</td><td align="center" valign="middle" >−11.879</td><td align="center" valign="middle" >Weak</td></tr><tr><td align="center" valign="middle" >MOL01225-dPLA2</td><td align="center" valign="middle" >−182.294</td><td align="center" valign="middle" >−182.294</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−48.616</td><td align="center" valign="middle" >−133.678</td><td align="center" valign="middle" >−13.198</td><td align="center" valign="middle" >Weak</td></tr></tbody></table></table-wrap><p>Note: dH indicates the enthalpy difference, to present the enthalpy difference in the presence of the protein-ligand complex and the protein and ligand alone; MM: van der Waals and electrostatic energy (COU + VDW); PB: polar solvation; SA: nonpolar solvation; COU: electrostatic energy; VDW: van der Waals; the dG indicates the free energy difference, to assess the binding forces between the ligand receptors, the more negative the dG, Me means stronger binding.</p><p>ingredient (MOL006957) of Pinellia in Chinese prescription [<xref ref-type="bibr" rid="scirp.133124-ref42">42</xref>] has potential medicinal value. In the course of this experiment, it was found that MOL006957 showed outstanding advantages compared with other compounds in the screening. The pharmacokinetic analysis, molecular docking or molecular dynamics simulation, indicated that the ligand binding is quite stable, and can play an important role in the treatment of snake venom and neutralization of dPLA2. However, whether this molecule can be used to inhibit snake venom inside the human body remains unclear, further in vivo experiments are needed to validate the potential clinical utility of the molecules identified.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s6"><title>Cite this paper</title><p>Xiao, X.Y., Lai, M.Y., Rao, Z.C., Huang, J.Z., Xie, Y.W. and Zhang, H.B. (2024) In Silico Screening of Potential Inhibitors against dPLA2 from Named Chinese Herbs for Identification of Compounds with Antivenom Effects Due to Deinagkistrodon acutus Snake Bites. American Journal of Molecular Biology, 14, 107-125. https://doi.org/10.4236/ajmb.2024.143009</p></sec><sec id="s7"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.133124-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2007) Rabies and Envenomings. A Neglected Public Health Issue. Geneva. &lt;br&gt;https://www.who.int/publications/i/item/9789241563482 </mixed-citation></ref><ref id="scirp.133124-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Guti&amp;#233;rrez, M.J., Warrell, A.D. and Williams, J.D. (2017) The Need for Full Integration of Snakebite Envenoming within a Global Strategy to Combat the Neglected Tropical Diseases: The Way Forward. &lt;i&gt;PLOS Neglected Tropical Diseases&lt;/i&gt;, 7, e2162.</mixed-citation></ref><ref id="scirp.133124-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Guti&amp;#233;rrez, M.J., Le&amp;#243;n, G. and Burnouf, T. (2011) Antivenoms for the Treatment of Snakebite Envenomings: The Road Ahead. &lt;i&gt;Biologicals&lt;/i&gt;, 3, 129-142. &lt;br&gt;https://doi.org/10.1016/j.biologicals.2011.02.005</mixed-citation></ref><ref id="scirp.133124-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kasturiratne, A., Wickremasinghe, R.A., Silva, D.N., &lt;i&gt;et al.&lt;/i&gt; (2008) The Global Burden of Snakebite: A Literature Analysis and Modelling Based on Regional Estimates of Envenoming and Deaths. &lt;i&gt;PLOS Medicine&lt;/i&gt;, 11, e218. &lt;br&gt;https://doi.org/10.1371/journal.pmed.0050218</mixed-citation></ref><ref id="scirp.133124-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Mar&amp;#237;a, J.G., Thierry, B., Harrison, R.A., &lt;i&gt;et al.&lt;/i&gt; (2015) A Call for Incorporating Social Research in the Global Struggle against Snakebite. &lt;i&gt;PLOS Neglected Tropical Di&lt;/i&gt;&lt;i&gt;s&lt;/i&gt;&lt;i&gt;eases&lt;/i&gt;, 9, e0003960. &lt;br&gt;https://doi.org/10.1371/journal.pntd.0003960</mixed-citation></ref><ref id="scirp.133124-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Nie, X.K., He, Q.Y. and Zhou, B. (2021) Exploring the Five-Paced Viper (&lt;i&gt;Deinagk&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;strodon acutus&lt;/i&gt;) Venom Proteome by Integrating a Combinatorial Peptide Ligand Library Approach with Shotgun LC-MS/MS. &lt;i&gt;The Journal of Venomous Animals and Toxins Including Tropical Diseases&lt;/i&gt;, 27, e20200196. &lt;br&gt;https://doi.org/10.1590/1678-9199-jvatitd-2020-0196</mixed-citation></ref><ref id="scirp.133124-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tasoulis, T. and Isbister, G.K. (2023) A Current Perspective on Snake Venom Composition and Constituent Protein Families. &lt;i&gt;Archives of Toxicology&lt;/i&gt;, 97, 133-153. &lt;br&gt;https://doi.org/10.1007/s00204-022-03420-0</mixed-citation></ref><ref id="scirp.133124-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Jin, H., Minrui, Z., Chu, X., Liang, J.Q. and Huang, F. (2022) Analysis of the Composition of &lt;i&gt;Deinagkistrodon acutus&lt;/i&gt; Snake Venom Based on Proteomics, and Its Antithrombotic Activity and Toxicity Studies. &lt;i&gt;Molecules&lt;/i&gt;, 27, Article 2229. </mixed-citation></ref><ref id="scirp.133124-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kong, Y., Sun, Q., Zhao, Q. and Zhang, Y. (2018) Purification and Characterization of a Novel Antiplatelet Peptide from &lt;i&gt;Deinagkistrodon acutus&lt;/i&gt; Venom. &lt;i&gt;Toxins&lt;/i&gt;, 10, Article 332. &lt;br&gt;https://doi.org/10.3390/toxins10080332</mixed-citation></ref><ref id="scirp.133124-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Gu, L.C., Zhang, H.L., Song, S.Y., Zhou, Y. and Lin, Z. (2002) Structure of an Acidic Phospholipase A2 from the Venom of &lt;i&gt;Deinagkistrodon acutus&lt;/i&gt; in a New Crystal Form. &lt;i&gt;Acta Biochimica et &lt;/i&gt;&lt;i&gt;Biophysica&lt;/i&gt;&lt;i&gt;s Inica&lt;/i&gt;, 34, 266-272. &lt;br&gt;https://doi.org/10.2210/pdb1ijl/pdb</mixed-citation></ref><ref id="scirp.133124-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Zou, Z., Zeng, F., Zhang, L., Niu, L., Teng, M. and Li, X. (2012) Purification, Crystallization and Preliminary X-Ray Diffraction Analysis of an Acidic Phospholipase A&lt;sub&gt;2&lt;/sub&gt; with Vasoconstrictor Activity from &lt;i&gt;Agkistrodon halys pallas&lt;/i&gt; Venom. &lt;i&gt;Acta Cry&lt;/i&gt;&lt;i&gt;s&lt;/i&gt;&lt;i&gt;tallographica&lt;/i&gt;, 68, 1329-1332. &lt;br&gt;https://doi.org/10.1107/S1744309112038523</mixed-citation></ref><ref id="scirp.133124-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chinnasamy, S., Selvaraj, G., Selvaraj, C., &lt;i&gt;et al.&lt;/i&gt; (2020) Combining &lt;i&gt;in Silico&lt;/i&gt; and &lt;i&gt;in Vitro&lt;/i&gt; Approaches to Identification of Potent Inhibitor against Phospholipase A2 (PLA2). &lt;i&gt;International Journal of Biological Macromolecules&lt;/i&gt;, 144, 53-66. &lt;br&gt;https://doi.org/10.1016/j.ijbiomac.2019.12.091</mixed-citation></ref><ref id="scirp.133124-ref13"><label>13</label><mixed-citation publication-type="book" xlink:type="simple">Costa, S.K.P., Camargo, E.A. and Antunes, E. (2017) Inflammatory Action of Secretory Phospholipases A2 from Snake Venoms. In: Cruz, L. and Luo, S., Eds., &lt;i&gt;To&lt;/i&gt;&lt;i&gt;x&lt;/i&gt;&lt;i&gt;ins and Drug Discovery&lt;/i&gt;, Springer, Dordrecht, 35-52. &lt;br&gt;https://doi.org/10.1007/978-94-007-6452-1_10</mixed-citation></ref><ref id="scirp.133124-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Timothy, O., Sarah, K., Abraham, O., &lt;i&gt;et al.&lt;/i&gt; (2020) Antivenin Plants Used for Treatment of Snakebites in Uganda: Ethnobotanical Reports and Pharmacological Evidences. &lt;i&gt;Tropical Medicine and Health&lt;/i&gt;, 48, Article No. 6.</mixed-citation></ref><ref id="scirp.133124-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Williams, J.D., Guti&amp;#233;rrez, J., Calvete, J.J., &lt;i&gt;et al&lt;/i&gt;. (2011) Ending the Drought: New Strategies for Improving the Flow of Affordable, Effective Antivenoms in Asia and Africa. &lt;i&gt;Journal of Proteomics&lt;/i&gt;, 74, 1735-1767. &lt;br&gt;https://doi.org/10.1016/j.jprot.2011.05.027</mixed-citation></ref><ref id="scirp.133124-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Maria, J.G., &lt;i&gt;et al.&lt;/i&gt; (2017) Snakebite Envenoming. &lt;i&gt;Nature Reviews Disease Primers&lt;/i&gt;, 3, Article No. 17063.</mixed-citation></ref><ref id="scirp.133124-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Stuart, A., Julien, S., Nessrin, A., &lt;i&gt;et al&lt;/i&gt;. (2018) The Paraspecific Neutralisation of Snake Venom Induced Coagulopathy by Antivenoms. &lt;i&gt;Communications Biology&lt;/i&gt;, 1, Article No. 34. &lt;br&gt;https://doi.org/10.1038/s42003-018-0039-1</mixed-citation></ref><ref id="scirp.133124-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Harrison, R.A., Casewell, N.R., Ainsworth, S.A. and Lalloo, D.G. (2019) The Time Is Now: A Call for Action to Translate Recent Momentum on Tackling Tropical Snakebite into Sustained Benefit for Victims. &lt;i&gt;Transactions of the Royal Society of Trop&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;cal Medicine and Hygiene&lt;/i&gt;, 113, 835-838. &lt;br&gt;https://doi.org/10.1093/trstmh/try134</mixed-citation></ref><ref id="scirp.133124-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Suveena, S., Saraswathy, V., &lt;i&gt;et al.&lt;/i&gt; (2022)&lt;i&gt; In Silico&lt;/i&gt; Screening of the Phytochemicals Present in &lt;i&gt;Clitoria ternatea&lt;/i&gt; L. as the Inhibitors of Snake Venom Phospholipase A&lt;sub&gt;2&lt;/sub&gt; (PLA&lt;sub&gt;2&lt;/sub&gt;). &lt;i&gt;Journal of Biomolecular Structure Dynamics&lt;/i&gt;, 41, 7874-7883.</mixed-citation></ref><ref id="scirp.133124-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Upasana, P., Alexandrino, P.F. and Mukherjee, A.K. (2022) Pharmacological Re-Assessment of Traditional Medicinal Plants-Derived Inhibitors as Antidotes against Snakebite Envenoming: A Critical Review. &lt;i&gt;Journal of Ethnopharmacology&lt;/i&gt;, 292, Article ID: 115208. &lt;br&gt;https://doi.org/10.1016/j.jep.2022.115208</mixed-citation></ref><ref id="scirp.133124-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Silva, D.P.D., Ferreira, S.D.S., Torres-R&amp;#234;go, M.,&lt;i&gt; et al.&lt;/i&gt; (2022) Antiophidic Potential of Chlorogenic Acid and Rosmarinic Acid against&lt;i&gt; Bothrops leucurus&lt;/i&gt; Snake Venom. &lt;i&gt;Biomedicine &amp; Pharmacotherapy&lt;/i&gt;, 148, Article ID: 112766. &lt;br&gt;https://doi.org/10.1016/j.biopha.2022.112766</mixed-citation></ref><ref id="scirp.133124-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Carvalho, B.M.A., Santos, J.D.L., &lt;i&gt;et &lt;/i&gt;&lt;i&gt;al&lt;/i&gt;&lt;i&gt;.&lt;/i&gt; (2013) Snake Venom PLA2s Inhibitors Isolated from Brazilian Plants: Synthetic and Natural Molecules. &lt;i&gt;BioMed Research I&lt;/i&gt;&lt;i&gt;n&lt;/i&gt;&lt;i&gt;ternational&lt;/i&gt;, 2013, Article ID: 153045. &lt;br&gt;https://doi.org/10.1155/2013/153045</mixed-citation></ref><ref id="scirp.133124-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J.J., Shi, D.J. and Li, K.H. (2005) Effect of Mohagan on the Inflammation and Bleeding Induced by Venom of Four Species of Pit Viper. &lt;i&gt;Ophistoma&lt;/i&gt;, 2, 65-68.</mixed-citation></ref><ref id="scirp.133124-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Liu, Z.K., Li, Q.P. and Zhou, W.Z. (2013) Effect of Clearing Heat, Cooling Blood and Detoxification on Coagulation Function of Patients Bitten by Five-Step Snake. &lt;i&gt;Journal of Nanjing University of Chinese Medicine&lt;/i&gt;, No. 1, 12-15.</mixed-citation></ref><ref id="scirp.133124-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Dey, A. and De, J.N. (2012) Phytopharmacology of Antiophidian Botanicals: A Review. &lt;i&gt;International Journal of Pharmacology&lt;/i&gt;, 8, 62-79. &lt;br&gt;https://doi.org/10.3923/ijp.2012.62.79</mixed-citation></ref><ref id="scirp.133124-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Pithayanukul, P., Laovachirasuwan, S., Bavovada, R., Pakmanee, N. and Suttisri, R. (2004) Antivenom Potential of Butanolic Extract of &lt;i&gt;E&lt;/i&gt;&lt;i&gt;clipta&lt;/i&gt;&lt;i&gt; &lt;/i&gt;&lt;i&gt;prostrata&lt;/i&gt; against Malayan Pit Viper Venom. &lt;i&gt;J&lt;/i&gt;&lt;i&gt;ournal of Ethnopharmacology&lt;/i&gt;, 90, 347-352. &lt;br&gt;https://doi.org/10.1016/j.jep.2003.10.014</mixed-citation></ref><ref id="scirp.133124-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Soares, A.M., Ticli, F.K., &lt;i&gt;et al.&lt;/i&gt; (2005) Medicinal Plants with Inhibitory Properties against Snake Venoms. &lt;i&gt;Current Medicinal Chemistry&lt;/i&gt;, 12, 2625-2641. &lt;br&gt;https://doi.org/10.2174/092986705774370655</mixed-citation></ref><ref id="scirp.133124-ref28"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ma</surname><given-names> Y.J. </given-names></name>,<etal>et al</etal>. (<year>2021</year>)<article-title>Research Progress on the Biology and Anti-Tumor of Artemisinins</article-title><source> &lt;i&gt;Modern Distance Education of Chinese Medicine&lt;/i&gt;</source><volume> 24</volume>,<fpage> 192</fpage>-<lpage>196</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.133124-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Ju, T.T., Liu, J.F. and Li, X.D. (2021) Research Progress on Extraction Method and Application of Salicylic Acid. &lt;i&gt;Tianjin Chemical Industry&lt;/i&gt;, No. 4, 7-9.</mixed-citation></ref><ref id="scirp.133124-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Fan, H.H., Wang, L.Q., Liu, W.L., &lt;i&gt;et al.&lt;/i&gt; (2020) Repurposing of Clinically Approved Drugs for Treatment of Coronavirus Disease 2019 in a 2019-Novel Coronavirus-Related Coronavirus Model. &lt;i&gt;Chinese Medical Journal&lt;/i&gt;, 133, 1051-1056. &lt;br&gt;https://doi.org/10.1097/CM9.0000000000000797</mixed-citation></ref><ref id="scirp.133124-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Zeng, L., Hou, J.J., Ge, C.H., &lt;i&gt;et al.&lt;/i&gt; (2022) Network Pharmacological Study on the Mechanism of Cynanchum Paniculatum (Xuchangqing) in the Treatment of Bungarus Multicinctus Bites. &lt;i&gt;B&lt;/i&gt;&lt;i&gt;io&lt;/i&gt;&lt;i&gt;M&lt;/i&gt;&lt;i&gt;ed&lt;/i&gt;&lt;i&gt; &lt;/i&gt;&lt;i&gt;Research&lt;/i&gt;&lt;i&gt; &lt;/i&gt;&lt;i&gt;International&lt;/i&gt;, 2022, Article ID: 3887072. &lt;br&gt;https://doi.org/10.1155/2022/3887072</mixed-citation></ref><ref id="scirp.133124-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Quach, N.D., Arnold, R.D. and Cummings, B.S. (2014) Secretory Phospholipase A&lt;sub&gt;2&lt;/sub&gt; Enzymes as Pharmacological Targets for Treatment of Disease. &lt;i&gt;Biochemical Pha&lt;/i&gt;&lt;i&gt;r&lt;/i&gt;&lt;i&gt;macology&lt;/i&gt;, 90, 338-348. &lt;br&gt;https://doi.org/10.1016/j.bcp.2014.05.022</mixed-citation></ref><ref id="scirp.133124-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Ru, J., Li, P., Wang, J., &lt;i&gt;et al.&lt;/i&gt; (2014) TCMSP: A Database of Systems Pharmacology for Drug Discovery from Herbal Medicines.&lt;i&gt; &lt;/i&gt;&lt;i&gt;Journal of Cheminformatics&lt;/i&gt;, 6, Article No. 13. &lt;br&gt;https://doi.org/10.1186/1758-2946-6-13</mixed-citation></ref><ref id="scirp.133124-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Daina, A., Michielin, O. and Zoete, V. (2017) SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules. &lt;i&gt;Scientific Reports&lt;/i&gt;, 7, Article No. 42717. &lt;br&gt;https://doi.org/10.1038/srep42717</mixed-citation></ref><ref id="scirp.133124-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Abraham, M.J., Murtola, T., Schulz, R., &lt;i&gt;et al.&lt;/i&gt; (2015) GROMACS: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops Tosupercomputers. &lt;i&gt;SoftwareX&lt;/i&gt;, 1, 19-25. &lt;br&gt;https://doi.org/10.1016/j.softx.2015.06.001</mixed-citation></ref><ref id="scirp.133124-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Cedro, A.C.R., Menaldo, L.D., Costa, R.T., &lt;i&gt;et al.&lt;/i&gt; (2018) Cytotoxic and Inflammatory Potential of a Phospholipase A&lt;sub&gt;2&lt;/sub&gt; from &lt;i&gt;Bothrops jararaca&lt;/i&gt; Snake Venom. &lt;i&gt;Journal of Venomous Animals and Toxins Including Tropical Diseases&lt;/i&gt;, 24, Article No. 33. &lt;br&gt;https://doi.org/10.1186/s40409-018-0170-y</mixed-citation></ref><ref id="scirp.133124-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Hikari, M.T., Airam, R., de Ferreira, L.L.M., &lt;i&gt;et al&lt;/i&gt;. (2022) Gallic Acid as a Non-Selective Inhibitor of &lt;i&gt;&amp;#945;&lt;/i&gt;/&lt;i&gt;&amp;#946;&lt;/i&gt;-Hydrolase Fold Enzymes Involved in the Inflammatory Process: The Two Sides of the Same Coin. &lt;i&gt;Pharmaceutics&lt;/i&gt;, 14, 368.</mixed-citation></ref><ref id="scirp.133124-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Costa, T.R., Francisco, A.F., Cardoso, F.F., &lt;i&gt;et al.&lt;/i&gt; (2021) Gallic Acid Anti-Myotoxic Activity and Mechanism of Action, a Snake Venom Phospholipase A&lt;sub&gt;2&lt;/sub&gt; Toxin Inhibitor, Isolated from the Medicinal Plant &lt;i&gt;Anacardium humile&lt;/i&gt;. &lt;i&gt;International Journal of Biological Macromolecules&lt;/i&gt;, 185, 494-512. &lt;br&gt;https://doi.org/10.1016/j.ijbiomac.2021.06.163</mixed-citation></ref><ref id="scirp.133124-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Bai, J., Qi, J., Yang, L., &lt;i&gt;et al.&lt;/i&gt; (2022) A Comprehensive Review on Ethnopharmacological, Phytochemical, Pharmacological and Toxicological Evaluation, and Quality Control of &lt;i&gt;Pinellia ternata&lt;/i&gt; (Thunb.) Breit. &lt;i&gt;Journal of Ethnopharmacology&lt;/i&gt;, 298, Article ID: 115650. &lt;br&gt;https://doi.org/10.1016/j.jep.2022.115650</mixed-citation></ref><ref id="scirp.133124-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Mao, R. and He, Z. (2020) &lt;i&gt;Pinellia ternata&lt;/i&gt; (Thunb.) Breit: A Review of Its Germplasm Resources, Genetic Diversity and Active Components. &lt;i&gt;Journal of Ethnopharmaco&lt;/i&gt;&lt;i&gt;l&lt;/i&gt;&lt;i&gt;ogy&lt;/i&gt;, 263, Article ID: 113252. &lt;br&gt;https://doi.org/10.1016/j.jep.2020.113252</mixed-citation></ref><ref id="scirp.133124-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Wang, L.C., Wang, D.G., Lin, T.D., &lt;i&gt;et al.&lt;/i&gt; (2022) Medication Rule and Potential Mechanism of the Core Drug Pairs in Treating Reflux Esophagitis by LIN Tiandong, the National Master of TCM. &lt;i&gt;Journal of Hunan University of Chinese Med&lt;/i&gt;&lt;i&gt;i&lt;/i&gt;&lt;i&gt;cine&lt;/i&gt;, 42, 1493-1501.</mixed-citation></ref><ref id="scirp.133124-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Luo, W., Ding, R., Guo, X., &lt;i&gt;et al.&lt;/i&gt; (2022) Clinical Data Mining Reveals Gancao-Banxia as a Potential Herbal Pair against Moderate COVID-19 by Dual Binding to IL-6/STAT3. &lt;i&gt;Computers in Biology and Medicine&lt;/i&gt;, 145, Article ID: 105457. &lt;br&gt;https://doi.org/10.1016/j.compbiomed.2022.105457</mixed-citation></ref></ref-list></back></article>